$43.88
▼ $-0.16
(-0.36%)
Vol 1.7M
12
Quality Score
ok
Deep Check
2/5
ok
Rev ✓
NI ✓
>IPO ✗
Mkt Cap
$11.8B
P/E
17.3
ROE
31.6%
Margin
29.6%
D/E
0.00
Beta
0.42
52W
$32–$50
Wall Street Consensus
27 analysts · Apr 20266
Strong Buy
9
Buy
11
Hold
1
Sell
0
Strong Sell
55.6%
Buy Rating
Price Chart
Similar Stocks
SMMT
Summit Therapeutics Inc
$13.0B
BBIO
BridgeBio Pharma Inc
$14.7B
NBIX
Neurocrine Biosciences Inc
P/E 33.0
$14.1B
MDGL
Madrigal Pharmaceuticals Inc
$13.2B
IONS
Ionis Pharmaceuticals Inc
$12.8B
BMRN
BioMarin Pharmaceutical Inc
P/E 21.9
$11.4B
PRAX
Praxis Precision Medicines Inc
$7.4B
ARWR
Arrowhead Pharmaceuticals Inc
$9.0B
PCVX
Vaxcyte Inc
$6.0B
Earnings
Beat rate: 100.0%
Next Report
May 11, 2026
EPS Estimate: $0.73
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $0.73 | — | — |
| Dec 2025 | $0.82 | $0.88 | +$0.06 |
| Sep 2025 | $0.63 | $0.69 | +$0.06 |
| Jun 2025 | $0.57 | $0.65 | +$0.08 |
Fundamentals Trend
| Metric | 2025-07-04 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | 27.7% | 27.7% | 27.7% | 27.7% | 31.6% | 31.6% |
| P/E (TTM) | 20.90 | 16.96 | 18.37 | 17.28 | 17.36 | 17.33 |
| Net Margin | 32.5% | 27.0% | 27.0% | 27.0% | 29.6% | 29.6% |
| Gross Margin | 96.6% | 96.6% | 96.6% | 96.6% | 96.6% | 96.6% |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 3.51 | 3.51 | 3.51 | 3.51 | 3.75 | 3.75 |
Key Ratios
ROA (TTM)
24.0%
P/S (TTM)
5.14
P/B
4.3
EPS (TTM)
$2.38
CF/Share
$0.36
Rev Growth 3Y
+10.4%
52W High
$49.62
52W Low
$31.90
$31.90
52-Week Range
$49.62
How does EXEL compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
EXEL valuation vs Biotechnology peers
P/E ratio
17.3
▼
8%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
5.1
▼
60%
below
peers
(12.9)
vs Peers
vs Industry
Undervalued
P/B ratio
4.3
▲
76%
above
peers
(2.5)
vs Peers
vs Industry
Overvalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
EXEL profitability vs Biotechnology peers
ROE
31.6%
▲
147%
above
peers
(-67.3%)
vs Peers
vs Industry
Top tier
Net margin
29.6%
▲
110%
above
peers
(-286.8%)
vs Peers
vs Industry
Below avg
Gross margin
96.6%
▲
23%
above
peers
(78.6%)
vs Peers
vs Industry
Weak
ROA
24.0%
▲
151%
above
peers
(-46.7%)
vs Peers
vs Industry
Top tier
EXEL financial health vs Biotechnology peers
D/E ratio
0.0
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
Low debt
Current ratio
3.8
▼
16%
below
peers
(4.4)
vs Peers
vs Industry
Below avg
Beta
0.4
▼
57%
below
peers
(1.0)
vs Peers
vs Industry
More volatile
EXEL fundamentals radar
EXEL
Peer median
Industry
EXEL profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
EXEL vs peers: key metrics
Latest AI Opinion
Grok
BUY
The price action shows a recent dip to a low of $39.71 on 2026-03-02 followed by a recovery to $41.41 close on 2026-03-23, positioning the current $41.37 as a solid entry point near support levels after volatility, with prior swings …
Mar 24, 2026